Steve Beuchaw
Stock Analyst at Morgan Stanley
(1.70)
# 2,203
Out of 4,667 analysts
104
Total ratings
64.52%
Success rate
11.09%
Average return
Main Sectors:
Stocks Rated by Steve Beuchaw
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Upgrades: Overweight | $49 → $51 | $42.09 | +21.17% | 1 | Feb 16, 2024 | |
| A Agilent Technologies | Initiates: Outperform | n/a | $128.57 | - | 20 | Dec 13, 2023 | |
| ALGN Align Technology | Maintains: Outperform | $711 → $770 | $223.87 | +243.95% | 11 | Jul 29, 2021 | |
| BRKR Bruker | Upgrades: Peer Perform | n/a | $53.37 | - | 9 | Nov 16, 2020 | |
| HSIC Henry Schein | Upgrades: Outperform | $68 | $73.73 | -7.77% | 4 | Apr 2, 2020 | |
| XRAY DENTSPLY SIRONA | Upgrades: Outperform | $66 | $18.52 | +256.37% | 6 | Apr 2, 2020 | |
| ILMN Illumina | Maintains: Equal-Weight | $320 → $288 | $131.68 | +118.71% | 9 | Jan 7, 2019 | |
| TMO Thermo Fisher | Maintains: Overweight | $254 → $260 | $512.84 | -49.30% | 7 | Oct 25, 2018 | |
| WAT Waters | Maintains: Equal-Weight | $204 → $211 | $357.77 | -41.02% | 13 | Oct 10, 2018 | |
| MYGN Myriad Genetics | Maintains: Overweight | $51 → $54 | $15.30 | +252.94% | 10 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $41 | $167.88 | -75.58% | 5 | Sep 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $323.69 | +3.49% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $334.85 | +0.04% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $19 | $20.06 | -5.28% | 5 | Aug 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $30,000 → $25,000 | $0.46 | +5,413,498.96% | 2 | Mar 15, 2017 |
Qiagen
Feb 16, 2024
Upgrades: Overweight
Price Target: $49 → $51
Current: $42.09
Upside: +21.17%
Agilent Technologies
Dec 13, 2023
Initiates: Outperform
Price Target: n/a
Current: $128.57
Upside: -
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $711 → $770
Current: $223.87
Upside: +243.95%
Bruker
Nov 16, 2020
Upgrades: Peer Perform
Price Target: n/a
Current: $53.37
Upside: -
Henry Schein
Apr 2, 2020
Upgrades: Outperform
Price Target: $68
Current: $73.73
Upside: -7.77%
DENTSPLY SIRONA
Apr 2, 2020
Upgrades: Outperform
Price Target: $66
Current: $18.52
Upside: +256.37%
Illumina
Jan 7, 2019
Maintains: Equal-Weight
Price Target: $320 → $288
Current: $131.68
Upside: +118.71%
Thermo Fisher
Oct 25, 2018
Maintains: Overweight
Price Target: $254 → $260
Current: $512.84
Upside: -49.30%
Waters
Oct 10, 2018
Maintains: Equal-Weight
Price Target: $204 → $211
Current: $357.77
Upside: -41.02%
Myriad Genetics
Oct 10, 2018
Maintains: Overweight
Price Target: $51 → $54
Current: $15.30
Upside: +252.94%
Sep 28, 2018
Maintains: Overweight
Price Target: $21 → $41
Current: $167.88
Upside: -75.58%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $323.69
Upside: +3.49%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $334.85
Upside: +0.04%
Aug 31, 2018
Maintains: Underweight
Price Target: $21 → $19
Current: $20.06
Upside: -5.28%
Mar 15, 2017
Downgrades: Underweight
Price Target: $30,000 → $25,000
Current: $0.46
Upside: +5,413,498.96%